- Home
- KUKE vs IMMX Comparison
KUKE vs IMMX Comparison
Compare KUKE & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- IMMX
- Stock Information
- Founded
- KUKE 2002
- IMMX 2014
- Country
- KUKE China
- IMMX United States
- Employees
- KUKE N/A
- IMMX N/A
- Industry
- KUKE Other Consumer Services
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- KUKE Real Estate
- IMMX Health Care
- Exchange
- KUKE Nasdaq
- IMMX Nasdaq
- Market Cap
- KUKE 21.2M
- IMMX 61.1M
- IPO Year
- KUKE 2021
- IMMX 2021
- Fundamental
- Price
- KUKE $0.34
- IMMX $2.20
- Analyst Decision
- KUKE
- IMMX Strong Buy
- Analyst Count
- KUKE 0
- IMMX 1
- Target Price
- KUKE N/A
- IMMX $7.00
- AVG Volume (30 Days)
- KUKE 102.3K
- IMMX 223.0K
- Earning Date
- KUKE 01-31-2025
- IMMX 11-12-2024
- Dividend Yield
- KUKE N/A
- IMMX N/A
- EPS Growth
- KUKE N/A
- IMMX N/A
- EPS
- KUKE N/A
- IMMX N/A
- Revenue
- KUKE $14,784,158.00
- IMMX N/A
- Revenue This Year
- KUKE N/A
- IMMX N/A
- Revenue Next Year
- KUKE N/A
- IMMX $200.00
- P/E Ratio
- KUKE N/A
- IMMX N/A
- Revenue Growth
- KUKE 10.48
- IMMX N/A
- 52 Week Low
- KUKE $0.23
- IMMX $1.26
- 52 Week High
- KUKE $4.07
- IMMX $7.07
- Technical
- Relative Strength Index (RSI)
- KUKE 42.81
- IMMX 53.40
- Support Level
- KUKE $0.30
- IMMX $2.03
- Resistance Level
- KUKE $0.36
- IMMX $2.30
- Average True Range (ATR)
- KUKE 0.04
- IMMX 0.28
- MACD
- KUKE 0.01
- IMMX -0.02
- Stochastic Oscillator
- KUKE 46.24
- IMMX 43.06
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.